US FDA approves a weight loss drug for treating ‘serious’ fatty liver disease; here’s what you need to know

The FDA has approved semaglutide for treating MASH, a significant advancement in liver disease management. Semaglutide, previously used for weight loss and diabetes, addresses both weight reduction and liver health, offering a dual benefit. Clinical trials demonstrated that semaglutide led to MASH resolution in 63% of patients without worsening liver scarring, marking a breakthrough for fatty liver disease treatment.

Life Style